4//SEC Filing
Anthera Pharmaceuticals Inc 4
Accession 0001214659-17-003555
CIK 0001316175operating
Filed
May 21, 8:00 PM ET
Accepted
May 22, 8:45 PM ET
Size
5.8 KB
Accession
0001214659-17-003555
Insider Transaction Report
Form 4
Dickinson Klara
SVP & Chief Regulatory Officer
Transactions
- Award
Stock option (right to buy)
2017-05-20+43,750→ 43,750 totalExercise: $1.63Exp: 2027-05-20→ Common Stock (43,750 underlying)
Footnotes (1)
- [F1]This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027.
Documents
Issuer
Anthera Pharmaceuticals Inc
CIK 0001316175
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001316175
Filing Metadata
- Form type
- 4
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 8:45 PM ET
- Size
- 5.8 KB